267 related articles for article (PubMed ID: 11447159)
1. Immunoglobulin A-mediated protection against Bordetella pertussis infection.
Hellwig SM; van Spriel AB; Schellekens JF; Mooi FR; van de Winkel JG
Infect Immun; 2001 Aug; 69(8):4846-50. PubMed ID: 11447159
[TBL] [Abstract][Full Text] [Related]
2. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89).
van der Pol W; Vidarsson G; Vilé HA; van de Winkel JG; Rodriguez ME
J Infect Dis; 2000 Oct; 182(4):1139-45. PubMed ID: 10979910
[TBL] [Abstract][Full Text] [Related]
4. Targeting to Fcgamma receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis.
Hellwig SM; van Oirschot HF; Hazenbos WL; van Spriel AB; Mooi FR; van De Winkel JG
J Infect Dis; 2001 Mar; 183(6):871-9. PubMed ID: 11237803
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
6. Fc receptor-mediated immunity against Bordetella pertussis.
Rodriguez ME; Hellwig SM; Hozbor DF; Leusen J; van der Pol WL; van de Winkel JG
J Immunol; 2001 Dec; 167(11):6545-51. PubMed ID: 11714823
[TBL] [Abstract][Full Text] [Related]
7. Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils.
van Spriel AB; van den Herik-Oudijk IE; van Sorge NM; Vilé HA; van Strijp JA; van de Winkel JG
J Infect Dis; 1999 Mar; 179(3):661-9. PubMed ID: 9952373
[TBL] [Abstract][Full Text] [Related]
8. FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity.
van Egmond M; van Garderen E; van Spriel AB; Damen CA; van Amersfoort ES; van Zandbergen G; van Hattum J; Kuiper J; van de Winkel JG
Nat Med; 2000 Jun; 6(6):680-5. PubMed ID: 10835685
[TBL] [Abstract][Full Text] [Related]
9. Targeting of Porphyromonas gingivalis with a bispecific antibody directed to FcalphaRI (CD89) improves in vitro clearance by gingival crevicular neutrophils.
Kobayashi T; Takauchi A; van Spriel AB; Vilé HA; Hayakawa M; Shibata Y; Abiko Y; van de Winkel JG; Yoshie H
Vaccine; 2004 Dec; 23(5):585-94. PubMed ID: 15542178
[TBL] [Abstract][Full Text] [Related]
10. FcalphaRI (CD89) alleles determine the proinflammatory potential of serum IgA.
Wu J; Ji C; Xie F; Langefeld CD; Qian K; Gibson AW; Edberg JC; Kimberly RP
J Immunol; 2007 Mar; 178(6):3973-82. PubMed ID: 17339498
[TBL] [Abstract][Full Text] [Related]
11. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18).
van Egmond M; van Vuuren AJ; Morton HC; van Spriel AB; Shen L; Hofhuis FM; Saito T; Mayadas TN; Verbeek JS; van de Winkel JG
Blood; 1999 Jun; 93(12):4387-94. PubMed ID: 10361137
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives.
Ben Mkaddem S; Rossato E; Heming N; Monteiro RC
Autoimmun Rev; 2013 Apr; 12(6):666-9. PubMed ID: 23201915
[TBL] [Abstract][Full Text] [Related]
13. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
[TBL] [Abstract][Full Text] [Related]
14. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc.
Herr AB; Ballister ER; Bjorkman PJ
Nature; 2003 Jun; 423(6940):614-20. PubMed ID: 12768205
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
van Egmond M; van Spriel AB; Vermeulen H; Huls G; van Garderen E; van de Winkel JG
Cancer Res; 2001 May; 61(10):4055-60. PubMed ID: 11358825
[TBL] [Abstract][Full Text] [Related]
16. Peptide mimetics of immunoglobulin A (IgA) and FcαRI block IgA-induced human neutrophil activation and migration.
Heineke MH; van der Steen LPE; Korthouwer RM; Hage JJ; Langedijk JPM; Benschop JJ; Bakema JE; Slootstra JW; van Egmond M
Eur J Immunol; 2017 Oct; 47(10):1835-1845. PubMed ID: 28736835
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses.
Raeven RHM; Rockx-Brouwer D; Kanojia G; van der Maas L; Bindels THE; Ten Have R; van Riet E; Metz B; Kersten GFA
Sci Rep; 2020 Apr; 10(1):7396. PubMed ID: 32355188
[TBL] [Abstract][Full Text] [Related]
18. The Fc receptor for IgA (FcalphaRI, CD89).
Otten MA; van Egmond M
Immunol Lett; 2004 Mar; 92(1-2):23-31. PubMed ID: 15081523
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
20. IgA and FcαRI: Pathological Roles and Therapeutic Opportunities.
Breedveld A; van Egmond M
Front Immunol; 2019; 10():553. PubMed ID: 30984170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
